Insight Molecular Diagnostics (IMDX) executive compensation, 2026 proxy

Joshua Riggs, President & Chief Executive Officer, was paid $2.6M in 2025, up 230% from $786,077 the year before.

Filed
April 30, 2026
Pay year
2025
Named executives
3
CEO total pay
$2.6M+230% vs prior year
CEO pay in equity
74%$1.9M in awards
CEO 2025 Total Pay
$2,594,786Summary compensation table total
CEO Compensation Actually Paid
$4,432,538Per SEC Item 402(v)
CFO 2025 Total Pay
$1,679,126Andrea James
2025 Net Loss
$(50,222)In thousands

How Riggs was paid

$2.6M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary18%Bonus7%Stock awards23%Option awards51%All other compensation0%

Named executive officers

ExecutiveTotal
Joshua RiggsPresident & Chief Executive Officer$2,594,786
Andrea JamesChief Financial Officer$1,679,126
James LiuVP of Accounting, Controller, Treasurer & PAO$454,990

What changed and why

  • $2.6MCEO Joshua Riggs received total compensation of $2,594,786 in fiscal 2025, compared to $786,077 in fiscal 2024.
  • $4.4MThe CEO's compensation actually paid for fiscal 2025 was calculated at $4,432,538 based on SEC rules.
  • $1.7MChief Financial Officer Andrea James earned total compensation of $1,679,126 during the 2025 fiscal year.
  • Named executive officer compensation included grants of RSUs and stock options valued at grant date fair value.
  • The company changed its trading symbol on The Nasdaq Capital Market to IMDX on June 18, 2025.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.